Author

Sheldon L. Padgett

ORCID 0009-0002-6557-418XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

Alyssa L. WalkeriD· 1 shared Christopher D. CollieriD· 1 shared Christopher M. FulkersoniD· 1 shared Deep A. GandhiiD· 1 shared Edward M. GreenfieldiD· 1 shared Emily E. SeideniD· 1 shared Gabrielle J. KnafleriD· 1 shared Gavin P. Kinsella· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alyssa L. WalkerORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Repurposing Romidepsin for Osteosarcoma: Screening FDA-Approved Oncology Drugs with Three-Dimensional Osteosarcoma Spheroids

Emily E. Seiden, Spencer M. Richardson, Leah A. Everitt, Gabrielle J. Knafler, Gavin P. Kinsella, Alyssa L. Walker, Venetia A. Whiteside, James D. Buschbach, Deep A. Gandhi, Mohammad Reza Saadatzadeh, L. Daniel Wurtz, Patrick J. Getty, Sheldon L. Padgett, Rance M. Gamblin, Michael O. Childress, , Edward M. Greenfield

This paper identifies romidepsin as a promising repurposed drug for osteosarcoma using 3D spheroid models, showing efficacy against metastatic cells and outperforming other HDIs.

bioRxiv · May 22, 2025 · PreprintCancer Biology